Premedication to Reduce Amivantamab Associated Infusion Related Reactions
| 対象疾患 | Carcinoma, Non-Small-Cell Lung |
|---|---|
| 相 | 第2相 |
| スポンサー | Janssen Research & Development, LLC |
| ステータス | 実施中（募集終了） |
| 参加者数 | 68 名 |
| 介入（薬剤） | Dexamethasone, Montelukast, Methotrexate, Amivantamab, Lazertinib |
| 開始日 | 2023年5月18日 |
| 完了日 | 2024年3月29日 |
| 結果公開日 | 2025年10月20日 |
概要
The purpose of the study is to separately assess the potential of dexamethasone, montelukast and methotrexate administration, prior to amivantamab infusion given through a needle in the vein, to decrease the incidence and/or severity of first-dose infusion related reactions.
Percentage of Participants With Infusion-related Reactions (IRRs) at Cycle 1 Day 1
| Cohort A: Dexamethasone 4 Milligrams (mg) | 83.3 Percentage of participants |
|---|---|
| Cohort A2: Dexamethasone 8 mg | 22.5 Percentage of participants |
| Cohort B: Montelukast 10 mg | 66.7 Percentage of participants |
| Cohort C: Methotrexate 25 mg | 83.3 Percentage of participants |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Risk and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer — M.D. Anderson Cancer Center
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tum — National Cancer Institute (NCI)
- Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients W — National Cancer Institute (NCI)
- A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients W — AstraZeneca
- Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therap — National Cancer Institute (NCI)
- Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With — National Cancer Institute (NCI)